Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

NIMOTOP 30 MG

NIMODIPINE : 30 MG · DIN 02325926 · LABORATOIRE X.0

Health Canada status: MARKETED

What is NIMOTOP?

NIMOTOP 30 MG contains NIMODIPINE : 30 MG. It is listed in the Health Canada Drug Product Database under DIN 02325926, held by LABORATOIRE X.0, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 18-Aug-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is NIMOTOP used for?

Adjunct to improve neurologic outcome following subarachnoid hemorrhage (SAH) from ruptured intracranial aneurysm.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

DIN02325926
Brand nameNIMOTOP
Generic / active ingredientNIMODIPINE : 30 MG
ManufacturerLABORATOIRE X.0
Strength30 MG
Dosage formTABLET
Route of administrationORAL
SchedulePrescription
ATC codeC08CA06 NIMODIPINE
AHFS class24:28.08
BiosimilarNo
Health Canada statusMARKETED
Status date18-Aug-2025
Original market date2009-07-24 00:00:00

How is it administered?

60 mg (two 30 mg tablets) orally every 4 hours for 21 consecutive days, starting within 4 days of SAH diagnosis. Swallow whole; do not crush.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Not explicitly detailed in provided text (standard section header exists but content is missing).

How is it supplied?

Not explicitly detailed in provided text (mentions 30 mg tablets).

Contraindications

Hypersensitivity to nimodipine; concomitant use with phenobarbital, phenytoin, carbamazepine, or rifampin.

Warnings and precautions

Caution in cerebral edema or raised intracranial pressure. Not for traumatic SAH. Monitor blood pressure (risk of hypotension). Caution in unstable angina or post-myocardial infarction.

What can be used instead?

Other Canadian products sharing ATC code C08CA06 NIMODIPINE. 1 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
NIMOTOP - CAP 30MG30 MGCAPSULEBAYER INCCANCELLED POST MARKETDIN 02155923
NIMOTOP CAP 30MG30 MGCAPSULEMILES CANADA INC. - PHARMACEUTICAL DIVISIONCANCELLED POST MARKETDIN 00596442
NIMOTOP I.V.-0.2MG/ML.2 MGLIQUIDBAYER INCCANCELLED POST MARKETDIN 02155915
NIMOTOP IV 0.2MG/ML0.2 MGLIQUIDMILES CANADA INC. - PHARMACEUTICAL DIVISIONCANCELLED POST MARKETDIN 01927124

Who else supplies NIMODIPINE worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. NIMODIPINE appears in 12 registered pack listings across 7 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for NIMOTOP

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Request a quote for NIMOTOP

Health Canada Drug Product Database (DPD), DIN 02325926. Last reviewed 2026-09-08. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.